EAP for the Treatment of Glioblastoma With PVSRIPO

Summary

This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications